skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

New developments in treatment of ovarian carcinoma: focus on trabectedin

Review

(2267) Views  (602) Full article downloads

Authors: Philippe A Cassier, Aude Duret, Olivier Trédan, et al

Published Date October 2010 Volume 2010:2 Pages 233 - 242
DOI: http://dx.doi.org/10.2147/CMAR.S9459

Philippe A Cassier1, Aude Duret1*, Olivier Trédan1, Nicolas Carrabin2, Pierre Méeus2, Isabelle Treilleux3, Jean-Paul Guastalla1, Isabelle Ray-Coquard1,4
1Département de médecine, 2Département de chirurgie, and 3Département d’anatomopathologie, Centre Léon Bérard, 4EA 4129 SIS Lyon, France *Deceased

Abstract: Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA repair machinery. Trabectedin has shown promising single-agent activity in pretreated patients with soft tissue sarcoma, and ovarian and breast cancer, and combination with various other chemotherapeutic drugs seems feasible. Toxicities are mainly hematologic and hepatic, with Grade 3–4 neutropenia and thrombocytopenia observed in approximately 50% and 20% of patients, respectively, and Grade 3–4 elevation of liver enzymes observed in 35%–50% of patients treated with trabectedin. The recently reported results of a large Phase III trial comparing pegylated liposomal doxorubicin (PLD) alone with a combination of PLD and trabectedin in patients with recurrent ovarian cancer showed improved progression-free survival with the combination of trabectedin and PLD, albeit at the price of increased toxicity. Current research focuses on the identification of predictive factors for patients treated with trabectedin, as well as the development of other combinations.

Keywords: chemotherapy, ovarian cancer, combination, drug development, DNA repair






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction
Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms
Pegylated liposomal doxorubicin in the management of ovarian cancer
Role of intranasal fentanyl in breakthrough pain management in cancer patients
The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage
Functionally induced changes in water transport in the proximal tubule segment of rat kidneys
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University